Expert Opinion on Therapeutic Patents

Papers
(The H4-Index of Expert Opinion on Therapeutic Patents is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data62
The role of patent analysis in target selection49
FAK inhibitors in cancer, a patent review – an update on progress38
Update on mGlu4 modulator patents: 2017 to present36
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)35
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)32
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)32
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)31
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities31
Caspase inhibitors: a review on recently patented compounds (2016–2023)30
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)27
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)23
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present23
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
An updated patent review of AKT inhibitors (2020 – present)23
A patent review of MAPK inhibitors (2018 – present)22
Inhibition of GTPase KRAS G12D : a review of patent literature21
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review21
Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)20
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)20
Antiprotozoal drugs: challenges and opportunities20
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)20
0.15892314910889